30073
| Randomized Phase III trial comparing immediate versus deferred nephrectomy in patients with synchronous metastatic renal cell carcinoma. |
22043
| Immediate or early salvage post-operative external radiotherapy combined with concomitant and adjuvant hormonal treatment versus immediate or early salvage post-operative external radiotherapy alone in pT3a-b R0-1 cNOMO/pT2R1 cN0M0, Gleason score 5-10 prostatic carcinoma. A phase III study. |
30072
| A Phase III Randomised Double-blind Study Comparing Sorafenib With Placebo In Patients With Resected Primary Renal Cell Carcinoma at High or Intermediate Risk of Relapse |
30061
| Phase I study of cisplatin, gemcitabine (+ paclitaxel) and lapatinib as first line treatment in advanced/metastatic urothelial cancer |
30021
| Randomized phase II trial of Docetaxel (Taxotere) and Oblimersen vs Taxotere alone in patients with HRPC |
30992
| Phase II study of Irinotecan (CPT 11) and Cisplatin (CDDP) in metastatic or locally advanced penile carcinoma. |
30012
| A Randomised Controlled Trial of Interferon-alpha, Interleukin-2 and 5-Fluorouracil vs Interferon-alpha Alone in Patients with Advanced Renal Cell Carcinoma. |
30004
| Chemoresection with 4 weekly intravesical instillations
of mitomycin C versus transurethral resection (TUR)
followed by one single immediate instillation
of mitomycin C in single, small, papillary stage Ta, T1 bladder tumors :
A prospective randomized phase III trial |
15011
| An international field of the reliability and validity of the QLQ-C30
and a disease-specific questionnaire module (QLQ-PR25) for assessing
quality of life of patients with prostate cancer. |
30994
| Randomized phase III trial comparing immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4, and/or N+M0 transitional cell carcinoma (TCC) of the bladder |
30001
| Radical Prostatectomy for Locally Advanced Prostate Cancer. A Feasibility Study. |
16006
| Open label phase II of MEN-10755 administered every 3 weeks in patients with
progressive hormone refractory prostate cancer |
30993
| A randomized phase II trial of sequential chemo-immunotherapy versus immunotherapy
alone in carcinoma in situ of the urinary bladder. |
30987
| Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and
cisplatin/gemcitabine in patients with metastatic or locally advanced
urothelial cancer without prior systemic therapy. |
30986
| Randomized phase II/III study assessing Gemcitabine/Carboplatin
and Methotrexate/Carboplatin/Vinblastine in previously untreated patients
with advanced urothelial cancer ineligible for Cisplatin based chemotherapy. |
30991
| Randomized phase III step-up study on initial antiandrogen monotherapy in
comparison with watchful waiting in asymptomatic T1-3 any G (any Gleason)
N0 or NxM0 prostate cancer patients without local treatment with curative intent.
|
16997
| EORTC 16997 :
A phase II study of SCH66336 (Farnesyl Protein Transferase Inhibitor)
in combination with Gemcitabine as second line treatment in patients
with advanced / metastatic urothelial tract tumor. |
30974
| A ranomized phase III study of sequential high-dose Cisplatinum/Etoposide/Ifosfamide plus stem cell support versus BEP in patients with poor prognosis Germ Cell Cancer |
30985
| Intermittent androgen deprivation in patients with stage
D2 prostate cancer-Phase III
|
30983
| Randomized phase II/III study of Taxol-BEP versus BEP in patients with
intermediate prognosis germ cell cancer |
30971
| A feasibility study of thorough transurethral resection (TURB) and escalated
dose M-VAC Chemotherapy as primary treatment of T2-T3a, N0-Nx, M0,
transitional cell carcinoma of the bladder, with the intention of bladder
preservation. |
30972
| RANDOMIZED PHASE III STUDY OF JM-216 ORAL PLATINUM PLUS PREDNISONE OR PREDNISONE ALONE IN PATIENTS WITH HORMONE REFRACTORY PROSTATE CANCER |
30982
| Carboplatin in the adjuvant treatment of stage I Seminoma |
30955
| Phase III adjuvant trial:Interleukin-2, Interferon-alpha and 5-Fluorouracil
for patients with high risk of relapse after surgical treatment for RCC |
22961
| Long term adjuvant hormonal treatment with LHRH analogue versus no further
treatment in locally advanced prostatic carcinoma treated by external irradiation
and a six months combined androgen blockade - A phase III study.
(Joint study of the EORTC Radiotherapy Cooperative Group and the EORTC Genito-Urinary Tract Cancer Cooperative Group)
|
30962
| Comparative study of intravesical BCG standard dose long-term maintenance versus
BCG 1/3 dose long-term maintenance versus BCG standard dose short-term maintenance
versus BCG 1/3 dose short-term maintenance in intermediate and high risk
Ta- T1 Papillary Carcinoma of the Urinary Bladder. |
30948
| A Phase II trial of C-BOP/BEP intensive induction chemotherapy for intermediate and poor prognosis metastatic germ cell tumors. |
30943
| Randomized phase III trial of immediate versus deferred hormonal therapy in patients with elevated PSA after definitive treatment for localised prostate cancer |
30954
| Intermittent maximal androgen blockade in patients with metastatic prostate cancer : Feasibility study. |
30951
| Randomized phase II trial of Interferon alpha-2a with and without 13-cis
Retinoic Acid in patients with progressive metastatic renal cell
carcinoma
Amendment protocol: Extension to a randomized phase III trial |
30952
| Quarter dose BCG on a papillary superficial bladder cancer. A phase II study on a marker lesion |
30944
| Randomized phase II trial assessing Estramustine and Vinblastine combination chemotherapy vs. Estramustine alone in patients with hormone escaped progressive metastatic prostate cancer |
30942
| A randomised Prospective Comparison of Two Schedules of Radiotherapy for Stage 1 Seminoma Testis Following Orchidectomy |
30947
| A randomized comparison of nephrectomy followed by Interferon Alpha 2-b (Intron-A) vs Interferon Alpha 2-b (Intron-A) alone in patients with advanced renal cell carcinoma. Phase III |
30941
| A randomized phase III study of 3 BEP versus 3 BEP-1 EP, and the 5-day schedule versus 3 days per cycle in good prognosis germ cell cancer |
30932
| Phase II study of 5-fluorouracil, Cisplatin and Interferon alpha in second line in advanced transitional cell cancer of the urothelial tract |
30931
| Phase II study of loboplatin in advanced urothelial tract tumors |
30924
| Randomized phase II / III study of high dose intensity M-VAC chemotherapy + G-CSF versus classic M-VAC in advanced urothelial tract tumors |
30906
| Phase III study to compare the efficacy of intravesical instillations of BCG versus Epirubicin in carcinoma in situ of the bladder |
30923
| Phase II trial of the efficacy and safety of roquinimex (linomide) in the treatment of renal cell carcinoma |
22911
| Phase III study of post-operative external radiotherapy in pathological stage
T3N0 prostatic carcinoma (Joint study of the EORTC Radiotherapy Cooperative Group
and the EORTC Genito-Urinary Tract Cancer Cooperative Group) |
30921
| A prospective multicenter randomized study comparing Strontium89 Chloride
and palliative local field radiotherapy in patients with hormonal escaped
advanced prostatic cancer |
30904
| A Prospective Randomized Ohase III study Comparing Radical Surgery to Elective Kidney Sparing Surgery for
Low Stage Renal Cell Carcinoma |
30911
| Phase III trial of intravesical instillation of Epirubicin, BCG or BCG + INH in intermediate and high risk pTa-pT1 papillary carcinoma of the urinary bladder |
30903
| Phase III trial of Flutamide versus Prednisone in hormone resistant metastatic prostate cancer |
30905
| Phase II trial of the efficacy and safety of linomide in the treatment of renal cell carcinoma |
30896
| Phase III study of BEP versus CEB in the management of good prognosis metastatic testicular (and extragonadal) teratoma (MRC/EORTC Collaborative Study) |
30901
| A RANDOMIZED PHASE III TO COMPARE TUR AND YAG-LASER FOLLOWED BY INTRAVESICAL CHEMOPROPHYLAXIS WITH Epirubicin in SINGLE RECURRENT, MULTIPLE PRIMARY OR RECURRENT Ta-T1 TCC OF THE BLADDER |
30902
| Phase II study of R75251 in patients with progressive, measurable, metastatic prostate cancer |
30895
| Phase III study of BEP versus BOP/VIP in the management of poor prognosis metastatic testicular and extragonadal teratoma (MRC/EORTC Collaborative Study) |
30897
| Phase II study of Mitomycin C and intravesical immunotherapy with BCG-RIVM in recurrent superficial transitional cell carninoma of the bladder |
30891
| Phase III study comparing early versus delayed orchidectomy, or early versus delayed treatment with a depot LHRH analogue (Buserelin) respectively, in patients with asymptomatic non metastatic prostate cancer T0-4 N0-2 M0 |
30893
| Phase III study comparing orchidectomy and orchidectomy + Mitomycin C in patients with metastatic prostate cancer with poor prognostic factors |
30892
| Phase III study comparing endocrine treatment with Flutamide or Cyproterone acetate in patients with painless metastatic prostate cancer with favorable prognostic factors |
30894
| Phase III study of primary chemotherapy (CMV) in T2G3, T3 and T4a, NO-X, M0 transitional cell carcinoma of the bladder (MRC/EORTC Collaborative Study) |
30886
| Phase II protocol to study mitomycin C in patients with advanced transitional cell carcinoma of the urinary tract resistant to or ineligible for first line chemotherapy |
30884
| Phase II protocol for the study of high dose Epirubicin in patients with progressive measurable metastatic prostate cancer |
30883
| Phase II study of high dose epirubicin in patients with progressive measurable metastatic non seminomatous germ cell tumours, including extragonadal tumours. (Jointly with the EORTC Early Clinical trials Cooperative Group - Protocol 16881) |
30885
| Randomized phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma |
30882
| Phase II study of vinblastine in patients with progressive measurable matastatic renal cell carcinoma |
30881
| Phase III trial of the investigation of the potentially curative value of lymphadenectomy in conjunction with radical nephrectomy for non-metastatic renal cell carcinoma |
30874
| Phase II study of cisplatin combination chemotherapy in high risk metastatic seminoma |
30869
| Phase II - III prospective randomized study to assess the effect of epirubicin in multiple bladder cancer |
30873
| A randomized phase III study of BEP (bleomycin, etoposide (VP-16), cisplatin) versus VIP (VP-16, ifosfamide, cisplatin) in intermediate risk patients with disseminated non-seminomatous testicular cancer |
30872
| PHASE II TRIAL OF TCNU IN PROGRESSIVE MEASURABLE METASTATIC RENAL CANCER - |
22863
| Phase III randomized clinical trial in high metastatic risk carcinoma of the prostate comparing pelvic radiotherapy plus LHRH analogue (Jointly with the EORTC Genito-Urinary Cancers Group) |
30871
| Phase II Chemotherapy with 5-Aza-2'-deoxycytidine in Patients with Nonseminomatous Testicular or Extragonadal Germ Cell Tumors That Are Progressive, Measurable, and Metastatic (Summary Last Modified 05/88) |
30868
| Randomized phase II study with (A) methotrexate, cisplatin and (B) vinblastine, methotrexate and cisplatin in patients with advanced transitional cell carcinoma of the urinary tract |
30861
| Phase II trial of intravesical instillation of BCG in carcinoma in situ of the urinary bladder |
30864
| Phase II chemoresection study of mitomycin C with a marker lesion followed by a phase III study randomizing between maintenance and no maintenance in multiple TaT1 bladder cancer |
30865
| A randomized phase III study comparing estracyt and mitomycin-C in hormone escaped advanced prostatic cancer |
30863
| Phase III prospective randomized trial for the study of TUR + a single intravesical instillation of Epirubicin versus TUR alone in single, primary or recurrent, Ta/T1 papillary carcinoma of the bladder. |
30866
| PHASE II STUDY OF MITOZOLOMIDE IN ADVANCED RENAL CANCER |
30867
| PHASE II STUDY OF Epirubicin IN ADVANCED TCC OF THE URINARY TRACT FOR PATIENTS RESISTANT TO OR INELIGIBLE FOR FIRST LINE CHEMOTHERAPY |
30847
| Phase II protocol to study management of stage I non-seminomatous testicular cancer with unilateral orchidectomy alone |
30851
| Phase II trial of Cisplatin and methotrexate in T3-4 N0-X M0 transitional cell carcinoma of the bladder |
30853
| Phase III protocol for a randomized prospective study of the treatment of patients with metastatic prostatic cancer to compare the therapeutic effect of orchidectomy versus LHRH-analogue depot preparation supplemented by an antiandrogen |
30846
| Phase III trial of endocrine treatment versus delayed endocrine treatment for patients with pN1-3M0 carcinoma of the prostate |
30852
| PHASE II STUDY OF Methotrexate IN PROGRESSIVE MEASURABLE PROSTATE CANCER |
30843
| Phase III trial of the treatment of patients with metastatic prostatic cancer to compare the therapeutic effect of orchidectomy versus LHRH-analogue supplemented by an anti-androgen |
30824
| Phase III trial for induction chemotherapy regimens (PVB-BEP-EP) in non pretreated patients stratified for high versus low volume metastases of non seminomatous testicular cancer |
30795
| EORTC PROTOCOL FOR REMISSION INDUCTION CHEMOTHERAPY WITH CIS-DIAMMINE-DICHLORO- PLATINUM, VINBLASTINE AND BLEOMYCIN IN PATIENTS WITH DISSEMINATED TESTICULAR NON-SEMINOMAS, RANDOMIZING FOR 75% VBL VERSUS 100% VBL. |
1310
| Impact of perceived sensitivity to medicines on adherence to medication and progression-free survival in patients with metastatic renal cell carcinoma treated with oral tyrosine kinase or m-tor inhibitors. |
30741
| Cancer of the prostate (stage III and IV) : natural history of patients with prostatic adenocarcinoma |
30742
| Cancer of the prostate (stage III and IV) : use of DES in untreated patients with advanced prostatic adenocarcinoma |
30763
| Phase II study of procarbazine and adriamycin in the treatment of hormone resistant prostatic cancer patients |
30764
| Comparison of adriamycin, cyclophosphamide, and adriamycin + 5-fluorouracil in patients with advanced bladder carcinoma |
30831
| Phase III trial of mitomycin C in primary and recurrent Ta-T1 papillary carcinoma of the bladder randomized between immediate vs delayed administration and maintenance vs no maintenance treatment |
30832
| Phase III trial of adriamycin in primary and recurrent Ta-T1 papillary carcinoma of the bladder randomized between immediate vs delayed administration and maintenance vs no maintenance treatment |
30835
| Phase II trial of human lymphoblastoid interferon (HUIFNa) in patients with differentiated teratoma, which develops post-chemotherapy and is not amenable to surgery |
30836
| Phase II trial of 4-deoxydoxorubicin in advanced renal cancer |
30751
| Phase III trial of thiotepa, versus VM26, versus no tretament in TI bladder cancer |
30761
| Phase III trial of cyproterone acetate versus medroxyprogesterone acetate versus DES in T3-T4 advanced prostatic cancer |
30762
| Phase III trial of estracyt versus stilboestrol in T3-T4 advanced prostatic cancer |
30781
| Doubled blind phase III trial of pyridoxine versus placebo in T1 Nx Mx and T1 No Mo transitional cell tumors of the bladder, after transurethral resection |
30782
| Phase III trial of thiotepa versus adriamycin versus cis-platinum in T1 papillary carcinoma of the bladder after transurethral resection |
30784
| Phase III trial of adriamycin plus 5-FU versus no treatment in patients with T3, Mo bladder tumors treated primarily by 1500 rads flash and radical cystectomy |
30791
| Phase III trial of adriamycin versus epodyl versus no treatment in primary and recurrent Ta and T1 papillary carcinoma of the bladder after transurethal resection |
30796
| E.O.R.T.C. STUDY COMPARING REMISSION MAINTENANCE CHEMOTHERAPY VERSUS NO MAINTENANCE THERAPY IN TESTICULAR NON-SEMINOMAS AFTER ACHIEVEMENT OF COMPLETE REMISSION BY INDUCTION CHEMOTHERAPY WITH CIS-DIAMMINE-DICHLORO-PLATINUM, VINBLASTINE, AND BLEOMYCIN. |
30797
| Phase II trial of vincristine in advanced bladder cancer |
30799
| Phase II trial of vindesine in advanced prostatic carcinoma |
30801
| Phase II trial of methyl-GAG in advanced renal carcinoma |
30802
| Phase II trial of cisplatin plus VM26 in advanced transitional cell carcinoma of the urinary tract |
30804
| Phase II trial of mitomycin-C in advanced prostatic cancer |
30805
| Phase III trial of bilateral orchidectomy versus bilateral orchidectomy plus CPA vs stilboestrol in metastatic prostatic cancer |
30811
| Phase II trial of vindesine in advanced renal cell cancer |
30841
| Phase II trial of weekly low dose 4'epi-adriamycin in patients with advanced prostatic carcinoma |
30842
| Phase II trial of combination of cisplatin and methotrexate in patients with advanced transitional cell carcinoma of the unitary tract |
30844
| Phase II trial of TGU in patients with advanced transitional cell carcinoma of the unitary tract |
30845
| Phase III trial of BCG-RIV vs mitomycin-C in primary and recurrent Ta-T1 papillary carcinoma and primary carcinoma in situ of the urinary bladder |
30806
| Phase II trial of embolization of renal cell carcinoma and subsequent nephrectomy in patients with metastatic disease |
30821
| Phase II trial of cisplatin + methotrexate in advanced transitional cell carcinoma of the urinary tract |
30822
| Phase II trial of mitoxantrone in advanced renal cell cancer |
30823
| Phase II trial of mitoxantrone in advanced bladder cancer |
30752BB
| Phase II in Bladder Cancer: VM 26, Adriamycin
|
1211
| Phase II randomized comparative trial of TAK-700 (orteronel) versus bicalutamide in metastatic prostate cancer patients failing 1st line treatment with LHRH agonists or surgical castration. |